Navigation Links

The traditional method for quantification and assessment of purity of DNA samples is spectrophotometric measurement at 260 and 280nm (1). It is generally accepted that a sample of pure, double-stranded DNA of 50 g/mL will have an absorbance at 260nm of 1.0 and that the ratio of absorbance at 260 and 280nm of this sample will be greater than 1.8 (2). If a sample has an A260 / A280 of less than 1.8, it is usually considered to be contaminated by protein. In such measurements, there is frequently little consideration given to the resolution or bandwidth of the spectrophotometer used for the measurements.

Instrument bandwidth is generally defined as the full width at half height of an absorbance band of a reference material that possesses a natural bandwidth less than or equal to the instrument bandwidth. The ideal reference material would be one with many absorbance bands, each having an infinitely small natural bandwidth. For this reason, the atomic lines of elements such as Hg are used as reference materials for determining instrument bandwidth.

Each sample will have a natural or Spectral Bandwidth and, thus, the ability of an instrument to accurately quantify components in a mixture will depend upon several factors, including natural bandwidths of the components and the instrument bandwidth. A widely accepted practice is to use a spectrophotometer with an instrument bandwidth of one tenth of the natural bandwidth of the analyte to be measured, 43 nm in the case of DNA. Thus, following the accepted practice, a spectrophotometer with an instrument bandwidth of = 4.3nm should be used to measure such samples. In the past few years there has been an increasing trend within life sciences toward the use of spectrophotometers with instrument bandwidths of 5nm or greater for quantification of DNA and for estim ation of DNA purity. This communication addresses the effects of instrument bandwidth on spectrophotometric determination of DNA concentration and purity.

Spectrophotometers used in this study were the Shimadzu models UV-2401PC (selectable bandwidth to 0.1nm), UV-1700 (fixed bandwidth, 1nm), and the UV-1240 (fixed bandwidth ,5nm). Calf thymus DNA and Bovine serum albumin were obtained from Sigma Chemical Company, St. Louis, MO. All other reagents were obtained from commercial sources and were of the highest available purity. Samples were prepared in 5mM KH2PO4 containing 145mM NaCl, pH 7.48. Semi-micro, far-UV quartz cells (~1.5mL) were used for all measurements.

An example of the spectrophotometric determination of DNA is illustrated in Figure 1. In this figure, a sample of approximately 73 g/mL calf thymus DNA in physiological buffer was measured using a Shimadzu UV-2401 spectrophotometer with an instrument bandwidth of 1.0nm. As illustrated in Figure 1, this sample of pure DNA has an absorbance maximum (1.47) and minimum (0.62) at approximately 260 and 230nm, respectively. The width at half-height of this spectrum is approximately 43 nm.The spectrum of this same DNA sample was measured using instruments of 1 and 5nm fixed-instrument bandwidth. These data are shown in Figure 2.

The data in Figure 2 indicate that there is very little difference in the spectrum of pure, double-stranded DNA measured using spectrophotometers of 1 and 5nm instrument bandwidth. The absorbance of the sample at 260nm and the A260/A280 ratios are comparable and well within experimental error. A similar comparison of spectra of 1mg/mL Bovine serum albumin is shown in Figure 3.

The spectra in Figure 3 have been offset by 0.1A in order to show the enhanced details in the spectrum of serum albumin measured in the 1nm bandwidth instrument. With enhanced resolution, the contributions from phenylalanine, tyrosine, and tryptophan become more obvious. These residues absorb between 260 and 280nm. However, as was the case for the sample of pure DNA, there was little difference in the measured absorbance (~0.6) and wavelength maximum (~278nm) of the protein sample in the two instruments.

A much different situation applies when DNA purity is assessed. In this situation, the instrument must discriminate between DNA and likely contaminants. These contaminants include protein, chloroform, phenol. Contamination by protein is usually indicated by a decrease in the A260/A280 ratio. Contamination by an extraction solvent such as phenol or chloroform is indicated by increased absorbance at 320nm. If the criterion for acceptable resolution of instrument bandwidth ten-fold less than peak wavelength difference (280-260nm = 20nm) is applied to samples containing DNA and protein, then an instrument with a bandwidth of = 2nm should be used. In this case, there are demonstrative advantages in using a spectrophotometer with a bandwidth of 1nm. The spectra of a sample containing 36g/mL DNA and 500 g/mL serum albumin are shown in Figure 4.

It is clear from these data that the A260/A280 ratios of the sample containing both DNA and protein measured in the 5nm bandpass instrument (1.11) and in the 1nm bandpass instrument (1.02) are not equivalent. While both ratios are significantly less than the value of 1.8 expected for pure DNA, this was a sample heavily weighted with protein (~93% by weight). A more interesting question is the lowest level of protein in a sample that can be determined by t his technique.

A series of samples with varying ratios of DNA and BSA were prepared in physiological buffer, and A260/A280 ratios for these samples were measured in spectrophotometers with 1 and 5nm bandwidth. The results are presented in Table 1.

The 1nm bandpass instrument was capable of discriminating a decrease in the A260/A280 ratio of DNA samples containing 10% by weight BSA, or contamination on the order of 10 g. This capability is more readily appreciated by examination of the data in Figure 5.

There appears to be little discernable change in the A260/A280 ratio of DNA-Protein mixtures measured using the 5nm bandpass instrument until approximately 20% by weight BSA or approximately twice the minimum level detected by the 1nm bandpass instrument.

Both 1nm and 5nm bandpass spectrophotometers are appropriate for measurement of pure DNA samples. But for determination of DNA purity, particularly at very low (~10g) amounts of protein, there are significant advantages to the use of a 1nm bandpass spectrophotometer.

1.Glasel, J.A., Validity of Nucleic Acid Purities Monitored by A260/A280 Absorbance Ratios, Biotechniques 18:62-63, 1995.

2. Maniatis T., E.F. Fritsch, and J. Sambrook, Molecular Cloning: A Laboratory Manual , Cold Spring Harbor Laboratory, Cold Springs Harbor, NY, 1982



Page: All 1 2 3 4

Related biology technology :

1. Evaluation of FlashPlate in a Helicase Assay
2. Accurate Evaluation of the Finnigan Surveyor Autosampler Performance using a Deferred Standard
3. Practical Aspects of Evaluation of Chromatographic Data in Size Exclusion Chromatography
4. Advancing the quality control methodology to assess isolated total RNA and generated fragmented cRNA
5. Flow cytometric analysis of human primary cells using the Agilent 2100 bioanalyzer and on-chip staining
6. Development of a Multiplex Bead-Based Assay for Antibody Screening of a Nonhuman Primate Colony on the Bio-Plex System
7. Using the Agilent 2100 bioanalyzer for quality control of protein samples prior to MS-analysis
8. Is Z factor the best assessment for the quality of cellular assays delivering higher content?
9. Quality control of antibodies using the 2100 bioanalyzer and the Protein 200 Plus assay
10. Quality assurance of RNA derived from laser microdissected tissue samples obtained by the PALM MicroBeam System using the RNA 6000 Pico LabChip kit.
11. Analysis of urine and seawater samples by ultrasonic nebulization with a high resolution ICP spectrometer
Post Your Comments:

(Date:2/16/2017)... 2017  ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology company ... better treatment for triple negative breast cancer (TNBC), announced today ... program. The YEi Start in ... help entrepreneurs grow their business in France ... companies selected to complete an intensive one week immersion in ...
(Date:2/16/2017)...   Capricor Therapeutics, Inc. (NASDAQ: ... first-in-class biological therapies for cardiac and other medical ... terminate its license agreement with the Mayo Clinic ... "Our decision to return these rights ... efforts to advance our core cell and exosome-based ...
(Date:2/16/2017)... , Feb. 16, 2017  Champions Oncology, Inc. ... the development and sale of advanced technology solutions and ... drugs, today announced the addition of new cohorts of ... These new models will expand Champions, product line in ... and neck cancer, AML, and non-small cell lung cancer ...
(Date:2/16/2017)... ... February 16, 2017 , ... ... Research Inc. has further extended its industry leading Biochemistry Services specifically targeting ... state-of-the-art cGMP techniques and methods for the biochemical and biosimilar characterization ...
Breaking Biology Technology:
(Date:1/30/2017)... , Jan. 30, 2017   Invitae Corporation ... fastest growing genetic information companies, today announced that it ... results and provide 2017 guidance on Monday, February 13, ... call that day at 4:45 p.m. Eastern / 1:45 ... management team will briefly review financial results, guidance, and ...
(Date:1/24/2017)... , Jan. 24, 2017  It sounds ... baby,s sock that monitors vital signs and alerts ... an infant,s oxygen saturation level drops. But pediatric ... alarm to parents, with no evidence of medical ... devices are marketed aggressively to parents of healthy ...
(Date:1/18/2017)... -- In vitro diagnostic (IVD) companies were very active in ... Kalorama Information expects that trend to continue – though ... uncertainty in reimbursement and healthcare reform in ... acquisitions landscape. Instead of looking to buy technology, the ... of their home country and also to increase their ...
Breaking Biology News(10 mins):